Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

5Total
P 2 (4)
P 3 (1)

Trial Status

Active Not Recruiting5

Clinical Trials (5)

Showing 5 of 5 trials
NCT03055013Phase 3Active Not Recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

NCT04071223Phase 2Active Not Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT04413123Phase 2Active Not Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT03541902Phase 2Active Not Recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03635892Phase 2Active Not Recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Showing all 5 trials

Research Network

Activity Timeline